Caribou Biosciences (CRBU) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tevogen (TVGN) has outperformed Caribou Biosciences (CRBU) over the past year, losing 80.5% versus a loss of 82.0%. Caribou Biosciences is the larger company by market cap ($51.3 million vs $46.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | TVGN |
|---|---|---|
| Share price | $0.4788 | $7.15 |
| Market cap | $51.33M | $46.56M |
| 1-day change | -0.50% | +1.27% |
| YTD return | -69.74% | -57.34% |
| 1-year return | -82.04% | -80.50% |
| 5-year return | -97.69% | — |
| EPS (TTM) | $-1.08 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $39.00 |
| 52-week low | $0.45 | $3.64 |
| Distance from 52-week high | -86.46% | -81.67% |
| Analyst consensus | buy | — |
| Avg. price target upside | +1100.92% | — |
| Average volume | 2.14M | 10.03K |
| Shares outstanding | 107.21M | 6.51M |
| Employees | 97 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
CRBU vs TVGN FAQ
Which is bigger, Caribou Biosciences or Tevogen?
Caribou Biosciences (CRBU) is larger, with a market capitalization of $51.33M compared with $46.56M for Tevogen (TVGN).
Which stock has performed better over the past year, CRBU or TVGN?
TVGN returned -80.50% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.